[ad_1]
Vaccine COVID-19, In other news. The one developed by the University of Oxford against coronavirus «is 70% effective». QWhen the vaccine was administered as a half dose, followed by a full dose at least one month apart, it was 90% effective. When given in two full doses at least one month apart, it was 62% effective. Combined analysis of both dosage regimens resulted in a mean efficacy of 70%. This was announced there AstraZeneca.
The strength of the vaccine developed in the Oxford laboratories is that it is decidedly cheaper than the others developed so far, as well as easier to store and therefore it can be available anywhere in the world. Therefore, if approved, it could play an important role in fighting the pandemic. The British government has already ordered 100 million doses vaccine developed by the University of Oxford, enough to immunize 50 million people.
The efficacy of the Oxford-AstraZeneca-Irbm vaccine therefore, it is equal to 90% with the optimal administration regimen, which involves inoculation of a half dose and a booster with a full dose after one month. Maximum tolerance for the elderly was highlighted. The cost of € 2.80 per full dose has been confirmed. AstraZeneca will submit data to global regulatory authorities for early or conditional approval of the vaccine. The company will also apply to the World Health Organization for emergency use for one accelerated path to vaccine availability in low-income countries. The full analysis of the interim results has been submitted for publication in a scientific journal.
The Oxford vaccine shows 70% protection against Covid, but was 90% effective when volunteers in the trial were given a half dose first followed by a full dose.
Andrew Pollard, director of the Oxford Vaccine Group, explained the findings to @JustinOnWeb pic.twitter.com/oQJYeHt4vL
– BBC Radio 4 today (@ BBCr4today) November 23, 2020
AstraZeneca CEO Pascal Soriot said that “today marks an important milestone in our fight against pandemic. The efficacy and safety of this vaccine confirm that it will be very effective against Covid-19 and will have an immediate impact on this health emergency. Soriot then explained that “the simple vaccine supply chain is our commitment nonprofit because there is broad, fair and timely access it means it will be affordable and available globally, supplying hundreds of millions of doses. ” In addition to the vaccine developed at Oxford, the UK government also ordered 40 million doses of the vaccine developed by Pfizer and BioNTech, which has been shown to be 95% effective.
AstraZeneca has the ability to make it available more than 3 billion doses of its own AZD1222 vaccine in 2021, pending approval. The vaccine, the company notes, can be stored, transported and handled under normal refrigeration conditions (2-8 degrees Celsius) for at least 6 months and administered within existing health facilities.
‘The Oxford news on the coronavirus vaccine they are encouraging. Important Italian companies are participating in the project, such as Irbm in Pomezia and Catalent in Anagni. We still need a lot of prudence, but it will be scientific research that will get humanity out of this crisis ”. This was stated by the Minister of Health, Roberto Speranza.
Covid Vaccine, Hope: “First doses early 2021, we see the light at the end of the tunnel”
Covid Vaccine, Oxford: “Ours is well tolerated and protects the elderly.” Efficacy data before Christmas
Modern vaccine “94.5% effective”. Fauci: extraordinary data, first doses at the end of December
Last updated: 16:24
© REPRODUCTION RESERVED
[ad_2]
